Email this article Late effects after treosulfan- and busulfan-based myeloablative conditioning for allogeneic HSCT in children with malignant diseases: a comparative study
- Authors: Skvortsova Y.V.1, Novichkova G.A.1, Maschan M.A.1, Balashov D.N.1, Papusha L.I.1, Shipitsina I.P.1, Shelikhova L.N.1, Voronin K.A.1, Skorobogatova E.V.2, Maschan A.A.1
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
- ФГБУ «Российская детская клиническая больница» Минздрава России
- Issue: Vol 17, No 2 (2018)
- Pages: 28-38
- Section: ORIGINAL ARTICLES
- Submitted: 20.09.2018
- Published:
- URL: https://hemoncim.com/jour/article/view/173
- DOI: https://doi.org/10.24287/1726-1708-2018-17-2-28-38
- ID: 173
Cite item
Full Text
Abstract
Treosulfan-based regimens used in conditioning for allogeneic HSCT (allo-HSCT) in children allow to reduce incidence of transplant-related mortality and early toxicity, but there are no data about long-term effects. We propose a retrospective comparative study of late complications after allo-HSCT in 135 children with hematologic malignancies, who got allo-HSCT between January 1994 and July 2011 and survived at least 1 year after HSCT. Five-year event free survival was 75.6% in the group of children who got busulfan and 66.5% in patients with treosulfan-based conditioning; 5-year nonrelapse mortality was 6% and 10.2%, respectively. Late effects analysis demonstrated that treosulfan-containing conditioning allowed to reduce the incidence of some late complications: hypergonadotropic hypogonadism cumulative incidence was 0 compared to 32.8% in busulfan-conditioning group (р = 0.012); the decrease in subclinical hypothyroidism, secondary cardiomyopathy and organic central nervous system pathology incidence was revealed. Thus treosulfan-based conditioning regimen is an effective approach in reducing of serious late complications after allogeneic HSCT when compared with data of busulfan-based conditioning long-term effects.
About the authors
Y. V. Skvortsova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
Author for correspondence.
Email: yuscvo@mail.ru
ORCID iD: 0000-0002-0566-053X
MD, hematologist, Hematopoietic Stem Cell Transplantation Department
Russia 117997, Moscow, Samory Mashela st., 1
Russian FederationG. A. Novichkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-2322-5734
Russian Federation
M. A. Maschan
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0003-1735-0093
Russian Federation
D. N. Balashov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0003-2689-0569
Russian Federation
L. I. Papusha
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0001-7750-5216
Russian Federation
I. P. Shipitsina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0001-8687-5497
Russian Federation
L. N. Shelikhova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0003-0520-5630
Russian Federation
K. A. Voronin
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0001-7578-9657
Russian Federation
E. V. Skorobogatova
ФГБУ «Российская детская клиническая больница» Минздрава России
ORCID iD: 0000-0003-4431-1444
Russian Federation
A. A. Maschan
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-0016-6698
Russian Federation
References
Supplementary files
